UNAIDS estimates that 14,000 new HIV-1 infections occur every day despite widespread knowledge of the protective effects of abstinence and condom use. There are no vaccine candidates or topical microbicides that are known to protect humans from HIV-1 infection. Hence, novel approaches to HIV prevention warrant urgent evaluation. Recognizing this situation, the National Institutes of Health and the Bill and Melinda Gates Foundation are sponsoring a randomized clinical trial of the safety and effectiveness of daily oral tenofovir versus placebo in Cambodia. Tenofovir is a potent inhibitor of HIV-1 replication that is licensed for treatment of AIDS and has prophylactic effects in animal models. The clinical trial in progress will evaluate whether chemoprophylaxis with tenofovir reduces that rate of seroconversion during the period of treatment. The same group of investigators now proposes to extend this work to test the hypothesis that daily oral tenofovir may have durable benefits (or risks), compared with placebo, that extend beyond the period of chemoprophylactic treatment, including attenuation of the course of infection among those who become infected despite chemoprophylaxis (aim 1) due to preservation of immune responses (aim 2a) from prolonged viral antigen exposure (aim 3a). The durability of these benefits will be assessed during longitudinal follow-up. Those who remain seronegative despite viral exposure during chemoprophylaxis may develop HIV-specific immune responses (aim 2b) due to viral exposure that is contained by the antiviral drug (aim 3b). Seronegative individuals previously exposed to chemoprophylaxis may become partially resistant to HIV-1 infection due to the measured immune responses, or other factors, that will decrease seroincidence or attenuate the course of infection if seroconversion occurs (aim 4). We will also determine whether drug resistant infections occur more commonly during and after chemoprophylaxis exposure, and whether the drug resistant viruses remain predominate over time even after chemoprophylaxis is stopped, which has implications for secondary transmission. The proposed prospective cohort of seroconverting and seronegative women who have completed the randomized trial of tenofovir versus placebo are uniquely valuable. The evaluation of post-chemoprophylactic benefits and risks bears directly on the utility of this novel approach to HIV-1 prevention. Even if tenofovir chemoprophylaxis is found to be ineffective in preventing seroconversion, the proposed cohort will provide uniquely valuable insights into how extremely early suppression of viral replication with antiviral agents may influence viral-host interactions that govern HIV-1 disease progression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI062333-01
Application #
6841471
Study Section
Special Emphasis Panel (ZRG1-AARR-C (02))
Program Officer
Ruiz, Monica S
Project Start
2004-09-01
Project End
2007-02-28
Budget Start
2004-09-01
Budget End
2005-02-28
Support Year
1
Fiscal Year
2004
Total Cost
$451,212
Indirect Cost
Name
J. David Gladstone Institutes
Department
Type
DUNS #
099992430
City
San Francisco
State
CA
Country
United States
Zip Code
94158
Mehrotra, Megha L; Rivet Amico, K; McMahan, Vanessa et al. (2018) The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men. AIDS Behav :
Grant, Robert M; Glidden, David V (2016) HIV moments and pre-exposure prophylaxis. Lancet 387:1507-8
Gandhi, Monica; Glidden, David V; Mayer, Kenneth et al. (2016) Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV 3:e521-e528
Solomon, Marc M; Schechter, Mauro; Liu, Albert Y et al. (2016) The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. J Acquir Immune Defic Syndr 71:281-6
Kuebler, Peter J; Mehrotra, Megha L; Shaw, Brian I et al. (2016) Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation. J Infect Dis 213:569-73
Gandhi, Monica; Glidden, David V; Liu, Albert et al. (2015) Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. J Infect Dis 212:1402-6
Grant, Robert M; Liegler, Teri; Defechereux, Patricia et al. (2015) Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS 29:331-7
Deutsch, Madeline B; Glidden, David V; Sevelius, Jae et al. (2015) HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV 2:e512-9
Kuebler, Peter J; Mehrotra, Megha L; McConnell, J Jeff et al. (2015) Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. Proc Natl Acad Sci U S A 112:8379-84
Solomon, Marc M; Lama, Javier R; Glidden, David V et al. (2014) Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS 28:851-9

Showing the most recent 10 out of 22 publications